Since somatic mutations in the TERT promoter and FGFR3 have been found in normal urothelium and are commonly reported in tumor tissues by The Cancer Genome Atlas (TCGA), they are considered potential driver mutations in the development of both low-grade and high-grade NMIBC. This evidence concerns the gene TERT and neoplasm.